{"transactions":[{"id":4622536,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":57500},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622535,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622534,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":350},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622533,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":39650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":350,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":39650},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622532,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.25,"expiration_date":"2028-05-10","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622531,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":47746,"price":63.6126,"value":3037247.1996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":98197,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622530,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":65104,"price":63.1205,"value":4109397.032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":145943,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622529,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":57500,"price":26.88,"value":1545600.0,"ownership":{"direct":true},"balance_after":211047,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622528,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":55000,"price":15.46,"value":850300.0,"ownership":{"direct":true},"balance_after":153547,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622527,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":350,"price":17.96,"value":6286.0,"ownership":{"direct":true},"balance_after":98547,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622526,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":270,"price":65.31,"value":17633.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":98197,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622525,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":63.6508,"value":190952.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided"}],"balance_after":98467,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622524,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":29021,"price":62.6552,"value":1818316.5592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":101467,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622523,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":63907,"price":61.994,"value":3961850.558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":130488,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622522,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":39650,"price":17.96,"value":712114.0,"ownership":{"direct":true},"balance_after":194395,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622521,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":39000,"price":25.25,"value":984750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026."}],"balance_after":154745,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":789864,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Performance-based restricted stock units","published_at":"2026-05-07T00:00:32.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."}],"balance_after":4250,"derivative":{"underlying":"Common  Stock","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001698262-26-000004","document":"form4-05062026_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000004/form4-05062026_080513.xml","form_type":"4"}},{"id":789863,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Performance-based restricted stock units","published_at":"2026-05-07T00:00:32.000Z","date":"2026-05-04","kind":"grant","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."}],"balance_after":8500,"derivative":{"underlying":"Common  Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001698262-26-000004","document":"form4-05062026_080513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000004/form4-05062026_080513.xml","form_type":"4"}},{"id":789862,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-05-07T00:00:32.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":2763,"price":43.95,"value":121433.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":115474,"source":{"system":"sec-edgar","filing":"0001698262-26-000004","document":"form4-05062026_080513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000004/form4-05062026_080513.xml","form_type":"4"}},{"id":789861,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-05-07T00:00:32.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."}],"balance_after":118237,"source":{"system":"sec-edgar","filing":"0001698262-26-000004","document":"form4-05062026_080513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000004/form4-05062026_080513.xml","form_type":"4"}},{"id":801775,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-04-23T20:05:06.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":9100,"price":39.09,"value":355719.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":113987,"source":{"system":"sec-edgar","filing":"0001698262-26-000003","document":"form4-04232026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000003/form4-04232026_040401.xml","form_type":"4"}},{"id":808147,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-04-16T01:48:44.000Z","date":"2026-04-13","kind":"grant","planned":true,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS."}],"balance_after":123087,"source":{"system":"sec-edgar","filing":"0001698262-26-000002","document":"form4-04162026_010440.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000002/form4-04162026_010440.xml","form_type":"4"}},{"id":921668,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-02-04T02:30:08.000Z","date":"2026-01-31","kind":"grant","planned":true,"acquired":true,"shares":53570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":53570,"derivative":{"exercise_price":33.095,"expiration_date":"2036-01-31","underlying":"Common Stock","underlying_shares":53570},"source":{"system":"sec-edgar","filing":"0001698262-26-000001","document":"form4-02032026_090205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000001/form4-02032026_090205.xml","form_type":"4"}},{"id":921667,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-02-04T02:30:08.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":12446,"price":32.87,"value":409100.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":109087,"source":{"system":"sec-edgar","filing":"0001698262-26-000001","document":"form4-02032026_090205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000001/form4-02032026_090205.xml","form_type":"4"}},{"id":921666,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-02-04T02:30:08.000Z","date":"2026-01-31","kind":"grant","planned":true,"acquired":true,"shares":20090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":121533,"source":{"system":"sec-edgar","filing":"0001698262-26-000001","document":"form4-02032026_090205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826226000001/form4-02032026_090205.xml","form_type":"4"}},{"id":958112,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2025-12-30T02:05:37.000Z","date":"2025-12-24","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":20.61,"expiration_date":"2027-02-13","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001698262-25-000005","document":"form4-12302025_021233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826225000005/form4-12302025_021233.xml","form_type":"4"}},{"id":958111,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2025-12-30T02:05:37.000Z","date":"2025-12-24","kind":"sale","planned":true,"acquired":false,"shares":60000,"price":40.103,"value":2406180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on February 13, 2017, with an expiration date of February 13, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $40.103, and the range of prices were between $38.00 and $42.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":101443,"source":{"system":"sec-edgar","filing":"0001698262-25-000005","document":"form4-12302025_021233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826225000005/form4-12302025_021233.xml","form_type":"4"}},{"id":958110,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2025-12-30T02:05:37.000Z","date":"2025-12-24","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":20.61,"value":1236600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 607 shares of Common Stock that were acquired by the Reporting Person on May 30, 2025, and 595 shares of Common Stock that were acquired by the Reporting Person on November 28, 2025, pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":161443,"source":{"system":"sec-edgar","filing":"0001698262-25-000005","document":"form4-12302025_021233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000169826225000005/form4-12302025_021233.xml","form_type":"4"}},{"id":1159048,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Performance-based restricted stock units","published_at":"2025-05-06T01:52:22.000Z","date":"2025-05-02","kind":"exercise","planned":true,"acquired":false,"shares":4920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a contingent right to receive one share of the common stock of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."}],"balance_after":4920,"derivative":{"underlying":"Common Stock","underlying_shares":4920},"source":{"system":"sec-edgar","filing":"0001415889-25-012056","document":"form4-05062025_010518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925012056/form4-05062025_010518.xml","form_type":"4"}},{"id":1159047,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2025-05-06T01:52:22.000Z","date":"2025-05-05","kind":"sale","planned":true,"acquired":false,"shares":3198,"price":21.05,"value":67317.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":100241,"source":{"system":"sec-edgar","filing":"0001415889-25-012056","document":"form4-05062025_010518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925012056/form4-05062025_010518.xml","form_type":"4"}},{"id":1159046,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2025-05-06T01:52:22.000Z","date":"2025-05-02","kind":"exercise","planned":true,"acquired":true,"shares":4920,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each PSU represents a contingent right to receive one share of the common stock of the Issuer."}],"balance_after":103439,"source":{"system":"sec-edgar","filing":"0001415889-25-012056","document":"form4-05062025_010518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925012056/form4-05062025_010518.xml","form_type":"4"}},{"id":1271491,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2025-02-13T02:30:01.000Z","date":"2025-02-10","kind":"exercise","planned":true,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a contingent right to receive one share of the common stock of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of  FILSPARI (sparsentan) in FSGS."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represents a contingent right to receive one share of the common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU represents a contingent right to receive one share of the common stock of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001415889-25-003824","document":"form4-02132025_020257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003824/form4-02132025_020257.xml","form_type":"4"}},{"id":1271490,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2025-02-13T02:30:01.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":5200,"price":23.53,"value":122356.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of the PSUs."}],"balance_after":98519,"source":{"system":"sec-edgar","filing":"0001415889-25-003824","document":"form4-02132025_020257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003824/form4-02132025_020257.xml","form_type":"4"}},{"id":1271489,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2025-02-13T02:30:01.000Z","date":"2025-02-10","kind":"exercise","planned":true,"acquired":true,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of  FILSPARI (sparsentan) in FSGS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each PSU represents a contingent right to receive one share of the common stock of the Issuer."}],"balance_after":103719,"source":{"system":"sec-edgar","filing":"0001415889-25-003824","document":"form4-02132025_020257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003824/form4-02132025_020257.xml","form_type":"4"}},{"id":1284586,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-05T01:30:29.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":58000,"derivative":{"exercise_price":20.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":58000},"source":{"system":"sec-edgar","filing":"0001415889-25-003067","document":"form4-02042025_080224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003067/form4-02042025_080224.xml","form_type":"4"}},{"id":1284585,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2025-02-05T01:30:29.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":8951,"price":19.78,"value":177050.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":95719,"source":{"system":"sec-edgar","filing":"0001415889-25-003067","document":"form4-02042025_080224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003067/form4-02042025_080224.xml","form_type":"4"}},{"id":1284584,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2025-02-05T01:30:29.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":104670,"source":{"system":"sec-edgar","filing":"0001415889-25-003067","document":"form4-02042025_080224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003067/form4-02042025_080224.xml","form_type":"4"}},{"id":1296294,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2025-01-24T01:40:03.000Z","date":"2025-01-22","kind":"sale","planned":true,"acquired":false,"shares":2437,"price":19.46,"value":47424.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,152 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024."}],"balance_after":83170,"source":{"system":"sec-edgar","filing":"0001415889-25-002008","document":"form4-01242025_010159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925002008/form4-01242025_010159.xml","form_type":"4"}},{"id":1411811,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2024-09-10T01:20:16.000Z","date":"2024-09-09","kind":"sale","planned":true,"acquired":false,"shares":4387,"price":11.52,"value":50538.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":84455,"source":{"system":"sec-edgar","filing":"0001415889-24-023096","document":"form4-09092024_090913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924023096/form4-09092024_090913.xml","form_type":"4"}},{"id":1411810,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2024-09-10T01:20:16.000Z","date":"2024-09-05","kind":"grant","planned":true,"acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,372 shares of Common Stock that were acquired by the Reporting Person on May 31, 2024 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":88842,"source":{"system":"sec-edgar","filing":"0001415889-24-023096","document":"form4-09092024_090913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924023096/form4-09092024_090913.xml","form_type":"4"}},{"id":1661516,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2024-02-02T21:05:41.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":65000,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001415889-24-002284","document":"form4-02022024_040225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002284/form4-02022024_040225.xml","form_type":"4"}},{"id":1661515,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:41.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":2590,"price":8.86,"value":22947.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":80720,"source":{"system":"sec-edgar","filing":"0001415889-24-002284","document":"form4-02022024_040225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002284/form4-02022024_040225.xml","form_type":"4"}},{"id":1661514,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:41.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":2174,"price":8.5316,"value":18547.6984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":83310,"source":{"system":"sec-edgar","filing":"0001415889-24-002284","document":"form4-02022024_040225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002284/form4-02022024_040225.xml","form_type":"4"}},{"id":1661513,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:41.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":85484,"source":{"system":"sec-edgar","filing":"0001415889-24-002284","document":"form4-02022024_040225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002284/form4-02022024_040225.xml","form_type":"4"}},{"id":1670870,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SENIOR VICE PRESIDENT, R&D"}}],"security":"Common Stock","published_at":"2024-01-25T21:10:16.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":2062,"price":8.96,"value":18475.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,373 shares of the Issuer's common stock acquired by the reporting person on November 30, 2023 pursuant to an employee stock purchase program."}],"balance_after":60484,"source":{"system":"sec-edgar","filing":"0001415889-24-001800","document":"form4-01252024_040111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924001800/form4-01252024_040111.xml","form_type":"4"}},{"id":1789082,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2023-09-06T00:13:54.000Z","date":"2023-09-05","kind":"sale","planned":false,"acquired":false,"shares":1815,"price":14.71,"value":26698.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":61173,"source":{"system":"sec-edgar","filing":"0001209191-23-048257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123048257/doc4.xml","form_type":"4"}},{"id":1789081,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2023-09-06T00:13:54.000Z","date":"2023-08-31","kind":"grant","planned":false,"acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 5,000 shares of the Issuer's common stock.  On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 477 shares of the Issuer's common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program."}],"balance_after":62988,"source":{"system":"sec-edgar","filing":"0001209191-23-048257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123048257/doc4.xml","form_type":"4"}},{"id":1894956,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-10","kind":"sale","planned":true,"acquired":false,"shares":825,"price":16.59,"value":13686.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on November 10, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":59211,"source":{"system":"sec-edgar","filing":"0001209191-23-029000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123029000/doc4.xml","form_type":"4"}},{"id":2035865,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2023-02-03T00:08:39.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date."}],"balance_after":6750,"derivative":{"underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0001209191-23-006432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006432/doc4.xml","form_type":"4"}},{"id":2035864,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2023-02-03T00:08:39.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":54500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":54500,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":54500},"source":{"system":"sec-edgar","filing":"0001209191-23-006432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006432/doc4.xml","form_type":"4"}},{"id":2035863,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2023-02-03T00:08:39.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":2590,"price":22.25,"value":57627.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":60036,"source":{"system":"sec-edgar","filing":"0001209191-23-006432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006432/doc4.xml","form_type":"4"}},{"id":2035862,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2023-02-03T00:08:39.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":62626,"source":{"system":"sec-edgar","filing":"0001209191-23-006432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006432/doc4.xml","form_type":"4"}},{"id":2044934,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2023-01-26T21:05:48.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":2062,"price":21.5,"value":44333.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 354 shares of the Issuer's common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program and 412 shares of the Issuer's common stock acquired by the reporting person on November 30, 2022 pursuant to an employee stock purchase program."}],"balance_after":42376,"source":{"system":"sec-edgar","filing":"0001209191-23-005036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123005036/doc4.xml","form_type":"4"}},{"id":2273427,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-05-13T00:49:57.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":813,"price":21.5163,"value":17492.7519,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":43672,"source":{"system":"sec-edgar","filing":"0001209191-22-028710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028710/doc4.xml","form_type":"4"}},{"id":2273426,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-05-13T00:49:57.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":750,"price":21.93,"value":16447.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":44485,"source":{"system":"sec-edgar","filing":"0001209191-22-028710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028710/doc4.xml","form_type":"4"}},{"id":2416365,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2022-02-02T21:19:01.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date."}],"balance_after":8000,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-22-006367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006367/doc4.xml","form_type":"4"}},{"id":2416364,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2022-02-02T21:19:01.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":9840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date."}],"balance_after":9840,"derivative":{"underlying":"Common Stock","underlying_shares":9840},"source":{"system":"sec-edgar","filing":"0001209191-22-006367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006367/doc4.xml","form_type":"4"}},{"id":2416363,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2022-02-02T21:19:01.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":39360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":39360,"derivative":{"exercise_price":27.5,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":39360},"source":{"system":"sec-edgar","filing":"0001209191-22-006367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006367/doc4.xml","form_type":"4"}},{"id":2416362,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-02-02T21:19:01.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":1125,"price":27.4,"value":30825.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":45235,"source":{"system":"sec-edgar","filing":"0001209191-22-006367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006367/doc4.xml","form_type":"4"}},{"id":2416361,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-02-02T21:19:01.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":9840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years."}],"balance_after":46360,"source":{"system":"sec-edgar","filing":"0001209191-22-006367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006367/doc4.xml","form_type":"4"}},{"id":2425116,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-01-26T21:37:33.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":1875,"price":24.98,"value":46837.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":36520,"source":{"system":"sec-edgar","filing":"0001209191-22-005083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122005083/doc4.xml","form_type":"4"}},{"id":2436755,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-01-12T21:06:28.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":2500,"price":27.4,"value":68500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":38395,"source":{"system":"sec-edgar","filing":"0001209191-22-003050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122003050/doc4.xml","form_type":"4"}},{"id":2436754,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2022-01-12T21:06:28.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 13, 2017, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 5,000 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person's Form 4 filed August 17, 2021 overstated the number of shares of the Issuer's common stock acquired by the reporting person on May 31, 2021 pursuant to an employee stock purchase program in the amount of 399 shares. The number of shares set forth in column 5 above has been adjusted to correct such overstatement and to include 563 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program."}],"balance_after":40895,"source":{"system":"sec-edgar","filing":"0001209191-22-003050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122003050/doc4.xml","form_type":"4"}},{"id":2599897,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-08-17T23:38:13.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":1407,"price":17.1183,"value":24085.4481,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":35731,"source":{"system":"sec-edgar","filing":"0001209191-21-052081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121052081/doc4.xml","form_type":"4"}},{"id":2599896,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-08-17T23:38:13.000Z","date":"2021-08-13","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 931 shares of the Issuer's common stock acquired by the reporting person on May 31, 2021 pursuant to an employee stock purchase program."}],"balance_after":37138,"source":{"system":"sec-edgar","filing":"0001209191-21-052081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121052081/doc4.xml","form_type":"4"}},{"id":2714346,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-05-13T20:13:17.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":1562,"price":19.46,"value":30396.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":31707,"source":{"system":"sec-edgar","filing":"0001209191-21-032322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121032322/doc4.xml","form_type":"4"}},{"id":2714345,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-05-13T20:13:17.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":1563,"price":19.14,"value":29915.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":33269,"source":{"system":"sec-edgar","filing":"0001209191-21-032322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121032322/doc4.xml","form_type":"4"}},{"id":2849881,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-18T23:26:09.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":1250,"price":28.67,"value":35837.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":34832,"source":{"system":"sec-edgar","filing":"0001209191-21-012062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121012062/doc4.xml","form_type":"4"}},{"id":2849880,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-18T23:26:09.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":1250,"price":27.35,"value":34187.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":36082,"source":{"system":"sec-edgar","filing":"0001209191-21-012062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121012062/doc4.xml","form_type":"4"}},{"id":2871693,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-09T21:30:57.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":2250,"price":31.58,"value":71055.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021."}],"balance_after":37332,"source":{"system":"sec-edgar","filing":"0001209191-21-008810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121008810/doc4.xml","form_type":"4"}},{"id":2871692,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-09T21:30:57.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":2250,"price":31.41,"value":70672.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021."}],"balance_after":39582,"source":{"system":"sec-edgar","filing":"0001209191-21-008810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121008810/doc4.xml","form_type":"4"}},{"id":2876578,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-05T21:49:21.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)  On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study."}],"balance_after":41832,"source":{"system":"sec-edgar","filing":"0001209191-21-008122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121008122/doc4.xml","form_type":"4"}},{"id":2881537,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-04T02:32:29.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":1125,"price":28.91,"value":32523.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":37332,"source":{"system":"sec-edgar","filing":"0001209191-21-007634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007634/doc4.xml","form_type":"4"}},{"id":2881536,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-04T02:32:29.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":2500,"price":28.91,"value":72275.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Form 4 filed on behalf of the Reporting Person on February 2, 2021, incorrectly totaled the number of shares in column 5 of Table I.  The number of shares outstanding prior to the transaction reported herein was 40,957 shares."}],"balance_after":38457,"source":{"system":"sec-edgar","filing":"0001209191-21-007634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007634/doc4.xml","form_type":"4"}},{"id":2885420,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-03T02:23:10.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":1125,"price":30.75,"value":34593.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":43457,"source":{"system":"sec-edgar","filing":"0001209191-21-007028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007028/doc4.xml","form_type":"4"}},{"id":2885419,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-03T02:23:10.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":2500,"price":30.75,"value":76875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":40957,"source":{"system":"sec-edgar","filing":"0001209191-21-007028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007028/doc4.xml","form_type":"4"}},{"id":2885418,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-02-03T02:23:10.000Z","date":"2021-01-31","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study."}],"balance_after":44582,"source":{"system":"sec-edgar","filing":"0001209191-21-007028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007028/doc4.xml","form_type":"4"}},{"id":2897600,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2021-01-26T01:58:19.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":57500,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":57500},"source":{"system":"sec-edgar","filing":"0001209191-21-005254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121005254/doc4.xml","form_type":"4"}},{"id":2897599,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2021-01-26T01:58:19.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 496 shares of the Issuer's common stock acquired by the reporting person on November 30, 2020 pursuant to an employee stock purchase program."}],"balance_after":39582,"source":{"system":"sec-edgar","filing":"0001209191-21-005254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121005254/doc4.xml","form_type":"4"}},{"id":2977356,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-11-18T02:00:13.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":2500,"price":23.96,"value":59900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.13,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":24086,"source":{"system":"sec-edgar","filing":"0001209191-20-058943","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120058943/doc4.xml","form_type":"4"}},{"id":2981047,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-11-14T02:25:23.000Z","date":"2020-11-13","kind":"sale","acquired":false,"shares":2500,"price":23.6224,"value":59056.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $23.96,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":26586,"source":{"system":"sec-edgar","filing":"0001209191-20-058418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120058418/doc4.xml","form_type":"4"}},{"id":2981046,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-11-14T02:25:23.000Z","date":"2020-11-11","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 13, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition."}],"balance_after":29086,"source":{"system":"sec-edgar","filing":"0001209191-20-058418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120058418/doc4.xml","form_type":"4"}},{"id":3023599,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-09-24T00:00:19.000Z","date":"2020-09-23","kind":"sale","acquired":false,"shares":1500,"price":18.48,"value":27720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation\nthat occurred upon the vesting of performance restricted stock units."}],"balance_after":24086,"source":{"system":"sec-edgar","filing":"0001209191-20-051736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120051736/doc4.xml","form_type":"4"}},{"id":3024909,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-09-23T01:20:50.000Z","date":"2020-09-22","kind":"sale","acquired":false,"shares":1500,"price":18.59,"value":27885.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation\nthat occurred upon the vesting of performance restricted stock units."}],"balance_after":25586,"source":{"system":"sec-edgar","filing":"0001209191-20-051615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120051615/doc4.xml","form_type":"4"}},{"id":3024908,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-09-23T01:20:50.000Z","date":"2020-09-18","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 592 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program."}],"balance_after":27086,"source":{"system":"sec-edgar","filing":"0001209191-20-051615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120051615/doc4.xml","form_type":"4"}},{"id":3150747,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-05-14T01:00:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":527,"price":16.9843,"value":8950.7261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":23494,"source":{"system":"sec-edgar","filing":"0001209191-20-029023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/doc4.xml","form_type":"4"}},{"id":3150746,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-05-14T01:00:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":812,"price":17.16,"value":13933.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":24021,"source":{"system":"sec-edgar","filing":"0001209191-20-029023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/doc4.xml","form_type":"4"}},{"id":3150745,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-05-14T01:00:15.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":813,"price":14.95,"value":12154.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":24833,"source":{"system":"sec-edgar","filing":"0001209191-20-029023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/doc4.xml","form_type":"4"}},{"id":3213429,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-03-12T23:45:55.000Z","date":"2020-03-10","kind":"sale","acquired":false,"shares":3250,"price":14.87,"value":48327.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.855 to $15.16,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":25646,"source":{"system":"sec-edgar","filing":"0001209191-20-018649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120018649/doc4.xml","form_type":"4"}},{"id":3220337,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-03-10T01:08:17.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":3250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 6,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria.  On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled."}],"balance_after":28896,"source":{"system":"sec-edgar","filing":"0001209191-20-017541","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120017541/doc4.xml","form_type":"4"}},{"id":3262903,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-02-19T21:05:59.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":1250,"price":16.55,"value":20687.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":25646,"source":{"system":"sec-edgar","filing":"0001209191-20-010482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120010482/doc4.xml","form_type":"4"}},{"id":3262902,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-02-19T21:05:59.000Z","date":"2020-02-14","kind":"sale","acquired":false,"shares":1250,"price":16.72,"value":20900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 961 shares of the Issuer's common stock acquired by the reporting person on May 30, 2019 and November 30, 2019 pursuant to an employee stock purchase program."}],"balance_after":26896,"source":{"system":"sec-edgar","filing":"0001209191-20-010482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120010482/doc4.xml","form_type":"4"}},{"id":3296666,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2020-02-01T01:19:12.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-005905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005905/doc4.xml","form_type":"4"}},{"id":3296665,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2020-02-01T01:19:12.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-005905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005905/doc4.xml","form_type":"4"}},{"id":3296664,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2020-02-01T01:19:12.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":55000,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-005905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005905/doc4.xml","form_type":"4"}},{"id":3296663,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2020-02-01T01:19:12.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27185,"source":{"system":"sec-edgar","filing":"0001209191-20-005905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005905/doc4.xml","form_type":"4"}},{"id":3523734,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2019-05-17T01:36:23.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":812,"price":17.76,"value":14421.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $17.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":18185,"source":{"system":"sec-edgar","filing":"0001209191-19-030659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030659/doc4.xml","form_type":"4"}},{"id":3523733,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Common Stock","published_at":"2019-05-17T01:36:23.000Z","date":"2019-05-14","kind":"sale","acquired":false,"shares":813,"price":17.78,"value":14455.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.74 to $17.90,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":18997,"source":{"system":"sec-edgar","filing":"0001209191-19-030659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030659/doc4.xml","form_type":"4"}},{"id":3531443,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Performance-based restricted stock units","published_at":"2019-05-11T01:41:54.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-029176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029176/doc4.xml","form_type":"4"}},{"id":3531442,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, R&D"}}],"security":"Employee stock option (right to buy)","published_at":"2019-05-11T01:41:54.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-029176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029176/doc4.xml","form_type":"4"}}],"next_cursor":"2019-05-11T01:41:54.000000Z,3531442"}